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Abstract
Membranous Nephropathy (MN) represents a large amount of Nephrotic Syndromes in the adult population and its
definitive diagnosis is currently carried out through biopsy. An autoimmune condition has been demonstrated in idiopathic
MN (iMN) in which some kidney structures are targeted by patient autoantibodies. Some candidate antigens have been
described and other likely involved target proteins responsible for the disease are not known yet. In this work our aim is to
identify these proteins by screening a lambda-phage library with patients’ sera. We enrolled four groups of patients: two MN
groups of 12 full iMN patients; one control group of 15 patients suffering from other renal diseases; one control group of 15
healthy individuals. A commercial cDNA phagemide library was screened using the above described sera, in order to detect
positive signals due to antigen-antibody bond. We detected one phagemide clone expressing a protein which was shown
to be targeted by the antibodies of the iMN sera only. Control sera were negative. The sequence analysis of cDNA matched
the Synaptonemal Complex protein 65 (SC65) coding sequence. Further proteomic analyses were carried out to validate our
results. We provide evidence of an involvement of SC65 protein as an autoimmune target in iMN. Considering the
invasiveness and the resulting risk coming from renal biopsy, our ongoing aim is to set a procedure able to diagnose
affected patients through a little- or non-invasive method such as blood sampling rather than biopsy.
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Introduction
Membranous Nephropathy (MN) is the most common cause of
nephrotic syndrome in adults [1,2]; it can be secondary to other
clinical conditions including infections, autoimmune diseases,
cancer and some toxic substances or drugs. However in most
cases (about 80%), MN is classified as idiopathic (iMN), since the
etiology of the nephropathy is still substantially unknown.
Although spontaneous remission is observed in about one third
of subjects, 40% of the patients develop end-stage renal failure
after about 10 years. [2,3] In histological preparations, a
thickening of the glomerular basal membrane is observable as a
consequence of subepithelial deposits of immune complexes with
immunoglobulins predominantly belonging to the IgG4 subclass.
[4,5] Such complexes are apparent in immunofluorescence
conducted with anti-IgG antibodies and in electron microscopy
as subepithelial electron-dense deposits. A pivotal role in the events
causing the glomerular lesions is played by the activation of
complement and the assembly on the podocyte surface of the
membrane attack complex C5b-9 that may be triggered by the
same immunodeposits. [6,7,8].
The autoimmune nature of the disease is thus strongly
suspected. This theory is supported by an abundant and consistent
scientific literature that started in the late fifties with the
description of the Heymann nephritis model. [9,10,11] The
autoantigen target of this model was identified in the rat podocyte
membrane protein named megalin. However, megalin has been
found neither in human podocyte nor in human MN immuno-
deposits and therefore it could not be proved responsible for the
human form of iMN. [12] The first antigen demonstrated to be
clearly involved in the human disease is neutral endopeptidase
(NEP), reported in some cases of antenatal membranous
glomerulonephritis. [13,14] This is a rare form of MN that can
arise in newborns from mothers carrying a genetic deficiency of
NEP: the protein is expressed by the podocytes of the embryo in
the uterus, and NEP deficient mothers produce anti-NEP
antibodies since their immune system recognizes it as a non-self
protein. These data supported the theory that podocytes act as a
source of antigens involved in the in situ formation of subepithelial
immune complex deposits. More recently, these data were
confirmed (by reports) by L.H. Beck et al. [15], M. Prunotto et al.
[7] and M. Bruschi et al [16]. The first group demonstrated that
sera from iMN patients show specific immunoreactivity against the
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M-type phospholipase A2 receptor (PLA2R) in about 70% of cases.
This glycoprotein is expressed by podocytes and colocalizes with
IgG in the subepithelial immune complex deposits. The second
group (including the last two papers cited above ) found that aldose
reductase (AR), manganese superoxide dismutase (SOD2) and a-
enolase (ENO1) are targeted by iMN patients IgG4, thus
effectively adding three more targets to the iMN antigen list.
On the basis of evidence of an autoimmune pathogenesis of the
disease consisting in autoantibodies directed to primitive renal
antigens and considering that NEP, AR, SOD2, ENO1 and
PLA2R do not exclude a possible role for other antigens [17], we
looked for patients sera reactivity to a wide panel of renal proteins.
In particular, we screened a large number of lysis plaques from a
lambda phage cDNA expression library comparing MN and
control patients sera. Candidates were further validated by
immune screenings and immunofluorescence techniques.
Methods
Patients and Control Subjects
Twelve nephrotic patients affected by iMN for the discovery
phase and twelve nephrotic patients affected by iMN for the
confirmation phase were recruited. The diagnosis of iMN was
made on the basis of biopsy examination using immunofluores-
cence techniques and optical microscopy according to the
parameters of the ‘World Health Organization Centre for the Histological
Classification of Renal Diseases, 1982’. Patients with the following
characteristics were included in this study: biopsy-proven iMN,
age older than 18 years, proteinuria .2 g/day, creatinine
,1.8 mg/dL. Patients affected by connective-tissue diseases,
positive to ANA, ENA antiDNA, antiphospholipids antibodies,
ANCA, diabetes mellitus, neoplasia, Hepatitis B or C virus
infection, HIV or systemic diseases, patients younger than 18 years
at the time of biopsy were excluded.
Clinical data at the time of biopsy included serum creatinine,
glomerular filtration rate measured according to the MDRD
formula [18], proteinuria (g/24 h), systolic and diastolic blood
pressure.
Fifteen nephrotic patients affected by glomerulonephrites other
than iMN or secondary MN were recruited (4 with diabetic
nephropathy, 4 with focal glomerulosclerosis, 4 with type I
membranoproliferative glomerulonephritis, 3 with minimal
change disease). Histological diagnosis and collection of clinical
data were performed following the same procedures as for the
iMN patients. Fifteen normal subjects recruited among blood
donors and matched to the iMN patients for age and sex were also
recruited.
The samples were assigned numbers to render them anony-
mous. The institutional review board of our University Hospital
approved the study and written informed consent was obtained
from all of the subjects.
Kidney Biopsy
Normal renal tissue was obtained by a cadaveric kidney donor.
Biopsies from patients recruited for the study were clinically
indicated in order to assist with specific diagnosis. Biopsy was
performed with a standard technique (see Methods S1).
Immunofluorescence
OCT (Tissue Tek, Miles, Elkhart, IN) was the embedding
medium for biopsy sample freezing in liquid nitrogen. Samples
were subsequently cut into 3 mm sections by a cryostat (Leica
1720, Leica Mycrosystems, Heerbrog, Germany) and placed on
glass slides (SuperFrost, Gerhard Menzel, Brunswick, Germany)
for indirect immunostaining. Cryosections were fixed in modified
Carnoy solution for 10 minutes at 4uC and subsequently washed in
PBS. Non-specific binding was blocked by incubation in BSA 3%
w/v in PBS for 20 minutes at room temperature. Sections were
then incubated for 1 hour at 37uC with primary mouse anti-No55
antibody (BD Transduction Laboratories, BD Biosciences, San
Jose CA, USA) and mouse anti-human IgG4 (Invitrogen Corpo-
ration, Carlsbad CA, USA) or mouse anti-Synaptopodin (Abnova
Table 1. Clinical characteristics of patients.
Parameter Patient
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Gender M M M M F F M F M F M M M M M F M F F F F F F M
Age at diagnosis 44,4 77,3 37,7 75,9 63,6 68,5 40,7 49,1 66,4 72,6 88,7 75,1 21,4 69,3 77,1 48 64 70 29,2 85 76 67,6 38,6 50,6
Histologic stage I-II I II-III I-II II-III II-III III I I II-III II-III I III I I-II I II III I I II-III I II-III II
Serum creatinine (mg/dl)
at diagnosis 1,08 1,32 1,33 1,43 0,83 1,23 1,14 0,95 0,88 0,86 1,55 1,5 1,1 2 2 0,6 1,08 1,09 0,52 1 1,7 0,65 0,79 0,88
after 1 year 1,69 0,87 0,85 1,09 0,92 1,45 1,2 0,86 2,06 1,13 0,66 1,74
Serum albumin
at diagnosis 2,5 2,42 2,8 2,45 2,74 2,2 2 2,46 2,58 2,83 2,74 2,6 2,81 2,21 1,7 2,5 3,7 2,88 3,35 2,3 2,2 2,9 3,29 3,05
after 1 year 4,3 4,53 3,99 2,77 2,53 3,99 3,71 3,58 1,97 4,01 4,42 3,15
Proteinuria
at diagnosis 3,5 3 4,8 4,5 3,3 6,61 8 2,28 7,65 8 4,83 6,69 2,55 4,4 4,4 10 5,9 1,2 2,3 11,5 3,9 4,4 4,9 3,5
after 1 year 0,69 0,93 1,38 1,62 0,95 1 2,7 1,9 25 0,1 0 5,3
Anti-HCV NA N N N N N N N NA N NA N N N N N N N N N N N N N
Immunosuppressant
therapy
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y
ACEI/ARB N Y Y Y Y Y Y Y Y Y Y Y N N Y N N Y NA Y Y Y Y Y
doi:10.1371/journal.pone.0048845.t001
New Autoantigen in iMN
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Corporation, Taipei City, Taiwan) diluted 1:10 in blocking
solution. Alexa FluorH 488 goat anti-mouse IgG2a (1:1000) and
Alexa FluorH 568 goat anti-mouse IgG1 (1:1000) (Invitrogen) were
used as secondary antibodies. Negative controls were processed in
parallel using an equivalent concentration of a normal mouse
antiserum as primary antibody.
Figure 1. Second selection of positive clone. Many plaques from pickup of first positive signal have developed on another plate. Exogenous
proteins produced by single plaques have been adsorbed to this filter membrane, and tested for the immunoreactivity with iMN patient serum. The
difference between positive and negative plaques is apparent.
doi:10.1371/journal.pone.0048845.g001
Figure 2. Recombinant spot assay of each serum. Positively reacting sera are those showing the dark spot in the middle of the membrane,
where the recombinant SC65 protein was spotted.
doi:10.1371/journal.pone.0048845.g002
New Autoantigen in iMN
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e48845
Preparation of Patient Sera
A 10 ml blood sample was collected from every subject early in
the morning prior to biopsy and before the patient was indicated
for immunosuppressive therapy. Within a few minutes from
collection, serum was isolated by centrifugation (10006g, 7 min)
and stored immediately at –75uC. Prior to use, the serum samples
were pooled in four groups: (i) from 12 iMN patients (discovery
group), (ii) from other 12 iMN patients (confirmation group), (iii)
from 15 non-MN renal patients (assorted as described), and (iv)
from 15 healthy individuals. Preabsorption membranes were
obtained by plating approximately 5,000 plaque forming units
(pfu) of lambda phage carrying GAPDH cDNA and E. coli XL1-
Blue MRF’ strain in NZY top agar and laying nitrocellulose
membranes (Purabind 045 by Whatman, Dassel, Germany)
previously soaked in 10 mM IPTG and air-dried.
Each serum pool was diluted 1:100 in blocking solution (16
PBS, 3% BSA) and incubated with preabsorption membranes for
five times.
Immunoscreening of the cDNA Expression Library
A commercially available 8 pooled kidney cDNA expression
library (Stratagene, Cambridge, UK) was immune-screened with
sera from the discovery phase group, according to the manufac-
turer’s protocol.
Positive plaques were re-screened with the same pool of sera to
obtain the clonality. Afterwards, phages were recovered as
pBluescript plasmids. See Methods S1 for further information.
Serological Spot Assay
Screening of positive clones was carried out by a serological
spot assay, as previously described [19]. In brief, 40 ml of
exponentially growing E. coli XL1-Blue MRF’ were incubated
with 40 ml of monoclonal phagemide containing 5,000 pfu per
microliter; 0.7 ml of this mixture was spotted on a layer of NZY
top agar (0.7% agarose) containing 2.5 mM isopropyl b-D-
thiogalactoside laying on a NZY agar Petri plate. Once the
mixture was set and the liquid absorbed by agar, a nitrocel-
lulose membrane was laid on the plate and incubated at 37uC
overnight. Therefore membranes were washed with TBST,
blocked with 16 PBS 3% BSA and incubated overnight with
blocking solution containing serum 1:100, previously depleted of
lambda phage and E. coli XL1-Blue MRF’. On control
membranes, a mouse anti-human GAPDH monoclonal anti-
body (Santa Cruz Biotechnologies, Santa Cruz, CA) diluted
1:4000 was used. Membranes were washed again with TBST
and then incubated with sheep anti-human horseradish perox-
idase-conjugated IgG antibody (or sheep anti-mouse horseradish
peroxidase-conjugated IgG antibody in controls) (GE Health-
care, Little Chalfont, England) diluted 1:4000 in 16 PBS for
1 h. A further cycle of TBST washing was applied. Antigen-
Figure 3. SC65 and Synaptopodin staining of normal and iMN renal tissue. The immunofluorescence image shows normal (A, B, C) and iMN
kidneys (D, E, F) stained with monoclonal antibodies against SC65 (A, D) and synaptopodin (B, E). Pictures C and F result from the merge of A+B and
D+E respectively. Costaining with synaptopodin show that SC65 and synaptopodin are co-expressed in the cytoplasm of podocyte cells.
doi:10.1371/journal.pone.0048845.g003
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antibody complexes were detected by ECL Western Blotting
Detection System (GE Healthcare) and autoradiography film.
Plasmid Excision and Isolation
Clonal plasmids were obtained from phagemids according to
the manufacturer’s protocol. See Methods S1 for details.
Plasmids were then isolated following small-scale preparation
protocol.
Molecular Analyses
Plamids obtained as described were digested with BdaI and PvuI
restriction endonucleases and their inserts amplified for sequenc-
ing. See Methods S1 for further details.
Sequencing and Identification
Sequencing was performed using the BigDye Terminator v1.1
Cycle Sequencing Kit (Applied Biosystems), and clone inserts were
sequenced with an automated sequencer (ABI 3100). Sequence
alignment was carried out by searching nucleotide databases with
BLAST.
Recombinant Spot Assay
Single sera were tested on spots of commercial recombinant
protein SC65 (Abnova, Taipei City, Taiwan). Square 2-cm
nitrocellulose membranes were prepared by spotting 0.5 mm of
recombinant protein SC65 in the centre and blocked with 3% (w/
Figure 4. SC65 and IgG4 staining of iMN renal tissue. The immunofluorescence image shows an iMN kidney glomerulus (and a particular of it)
stained with monoclonal antibodies against SC65 (A, D) and IgG4 (B, E). Pictures C and F result from the merge of A+B and D+E respectively. The
costaining of SC65 and IgG4 deposits in iMN specimens shows a polarized expression of IgG4 in the subepithelial district adjacent to a cytoplasmic
expression of SC65.
doi:10.1371/journal.pone.0048845.g004
Figure 5. Western blotting of SC65 in subcellular fractions of
cultured differentiated podocytes. Cy, cytosolic fraction. Me,
membrane fraction. Nu, nuclear fraction. A band corresponding to SC65
is apparent in the cytosolic and membrane fractions.
doi:10.1371/journal.pone.0048845.g005
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v) BSA in 16PBS for 1 h. Membranes were incubated overnight
in PBS-diluted serum; they were thus washed three times in TBST
and incubated with sheep anti-human IgG HRP-conjugated
antibody 1:4000 in PBS for 1 h. A further cycle of TBST washing
was applied. Finally, immunocomplexes were detected by ECL
Western Blotting Detection System and autoradiography film.
Cell Culture
A human conditionally immortalized podocyte cell line [20] was
cultured and proteins from subcellular fractions were obtained as
previously described [7].
Polyacrylamide Gel Electrophoresis and Western Blotting
Fifteen mg lanes of subcellular fractions were loaded on a
standard 7.5% polyacrylamide gel in order to perform a gel
electrophoresis. Migrated proteins were thus electroblotted onto a
nitrocellulose membrane to undergo Western blotting analysis
using a primary mouse anti-No55 antibody (BD Transduction
Laboratories, BD Biosciences, San Jose CA, USA) diluted 1:1000
in blocking solution, and a sheep anti-mouse horseradish
peroxidase-conjugated IgG antibody as secondary antibody. The
ECL Western Blotting Detection System was used to obtain
images on the autoradiography film.
Results
Autoreactive Phagemide Plaque were Identified By
Pooled Sera of Patients
Twenty-four nephrotic patients affected by iMN, 12 patients for
the discovery phase and 12 for the confirmation phase were
recruited for this work (see the Methods section for details on
patient recruitment). The clinical characteristics of these patients
are described in Table 1.
In order to identify possible autoreactive immune responses,
pooled sera from 12 recruited iMN patients (discovery group) were
used to probe a kidney cDNA expression library derived from
normal kidney tissue whole mRNA. Sera were obtained at the
time point of kidney biopsies, and iMN diagnosis was confirmed
by immunofluorescence and histological procedures. Approxi-
mately 26105 recombinant clones of the library were screened by
the pooled serum.
Six positive clones were detected. Immunoreactive phage
plaques were then removed from the corresponding agar plates,
and eluted phages were re-plated at lower plaque density and re-
screened as above with patients sera to isolate specific, purified
phage (Figure 1).
Putatively positive phage plaques were tested through a
Serological Spot Assay to confirm the specificity of this immune
reactivity. Pooled sera from 12 iMN patients (confirmation group),
15 control subjects and 15 patients affected by other glomerulone-
phrites than MN were used. A strong positive signal for iMN
patients was found only from one out of six plaques (arbitrarily
coded Q8).
Q8 Identification by Restriction Fragment Analysis and
Sequencing
After obtaining the pBluescript double stranded phagemid from
the Q8 plaque, a restriction analysis using BdaI and PvuI
endonucleases was performed in order to excide the insert cDNA
and estimate its size. Vector double digestion with BdaI and PvuI
endonucleases led to three fixed-length fragments (325, 1045 and
1158 base pairs) and one fragment whose length is given by cDNA
insert plus 397 base pairs from flanking regions. The output of
digestion was examined by agarose gel electrophoresis, allowing to
infer that the putative length of cDNA fragment is about 2,600
base pairs.
The sequence analysis of the cDNA insert was performed by
searching matches in the GenBank database through the BLAST
algorithm. The search output pointed to a full identity with coding
sequence of Synaptonemal Complex protein SC65 (accession
number NM_006455), also known as Nucleolar Autoantigen
(No55). The cDNA length in Genbank entry is 2619 bp, and the
result is consistent with restriction analysis output. The identifi-
cation was confirmed by the assessment of phagemid plaques
expressing SC65 with monoclonal anti-No55 antibody.
Recombinant Spot Assay
Each serum was evaluated with respect to its immunoreactivity
to a spot of pure recombinant protein SC65 through an
immunological analysis of recombinant protein spots. The sera
of 24 iMN patients (control and validation sets), 15 non-MN
patients and 15 healthy subjects were tested. Positive reactivity of 8
out of 24 patients suffering from iMN was found. None of the 15
non-MN patients and 15 healthy subjects showed reactivity against
pure recombinant protein SC65 (Figure 2).
Considering that the clinical features iMN patients with a
positive test showed lower albumin levels and a higher creatinine
level, neither of these features reached statistical significance.
Immunofluorescence
An indirect immunofluorescence staining of renal specimens
using the monoclonal antibody against SC65 was carried out. Two
commercial monoclonal antibodies raised against SC65 were
tested: one of them resulted ineffective for any technique (data not
shown). Thus the focus was particularly placed on the second
antibody (see Methods), whose activity is certified for western
blotting but not for immunofluorescence techniques. In consider-
ation of these limitations, a significant SC65 signal was found in
the glomeruli of patients affected by iMN; this pattern was
substantially absent in the glomeruli of control tissue. Costaining
with synaptopodin showed that SC65 is expressed in the cytoplasm
of podocyte cells (Figure 3). The costaining of SC65 and IgG4
deposits in iMN specimens was also further investigated showing
no clear match, but rather a polarized expression of IgG4 in the
subepithelial district adjacent to a cytoplasmic expression of SC65
(Figure 4).
Western Blotting
SDS-PAGE of cultured podocyte subcellular fractions was
performed to find the possible localization of SC65 in the cell
(Figure 5). Standard electrophoresis did reveal several bands,
particularly in the cytoplasmic fraction, and in the membrane
fraction as a double band. This is probably due to a post-
translational modification of the protein migrating to the
membrane. No band is observable in the nuclear compartment.
Discussion
Membranous nephropathy is characterized by an accumulation
of immune deposits, mainly of the IgG4 immunoglobulin subclass,
on the outer aspect of the glomerular basement membrane. The
debate on therapeutic management of patients affected by
membranous nephropathy has been a regular theme not yet
thoroughly addressed. [21,22,23] Steroids, cytotoxic drugs and
anti-CD20 agents showed a significant benefit in selected cohorts
of patients, reinforcing the hypothesis of a humoral autoimmune
nature of the disease. [5,6,7,9,10,11,14,15,17,24].
New Autoantigen in iMN
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Nevertheless, the need for using such an unspecific therapy
clearly provides evidence of an unsatisfactory knowledge of the
underlying pathogenetic mechanisms. A more specific concept-
driven therapy is thus urgently requested and obviously this cannot
leave out the knowledge of the nature of immune deposits. We
have conducted a clone library screening in the attempt to
discover putative antigens representing the target of this autoim-
mune process.
Our work has pointed out a new protein as a potential
candidate antigen for the iMN, i.e. Human Synaptonemal
Complex protein SC65, also known as Nucleolar protein No55.
By screening a phage library expressing renal proteins, we found a
strong and quite specific reactivity for this antigen in the serum of
patients affected by iMN. On the other hand, we could not detect
the previously described autoantigens of iMN, probably because of
the intrinsic limitations of protein representation in phage
libraries. [25].
SC65 is a protein first characterized as an autoantigen in one
case of interstitial cystitis (IC) in a patient not suffering from kidney
diseases, and it was described as localized in the particulate
compartment of the interphase nucleolus, with a distribution
distinct from that of the nucleolar protein B23. [26].
Even if SC65 identified in the interphase nucleolus suggests a
role in mitotic processes, an alternative role of this protein in
meiosis was also debated: our data do not confirm the nucleolar
localization of SC65; rather, we detected it in the non-nuclear
compartments through histological evaluation and western blot
analysis. SC65 expression was described in several normal human
tissues: the highest mRNA expression levels were detected in
ovaries, pancreas and prostate, whereas lower levels were retrieved
in other tissues. Human renal expression has been demonstrated
by Northern Blot analysis with an intermediate intensity between
the low expression of the liver and the strong expression of the
prostate. [27] An involvement of this protein has also been shown
in patients suffering from prostate cancer as a tumour-associated
autoantigen. [27].
Both autoimmune (IC) and cancer (prostate cancer) conditions
were systematically investigated and excluded in the cohort of
iMN patients recruited for this work. To our knowledge, the
protein isolated in this study did not correspond to any candidate
iMN antigen previously described. It is not clear which mechanism
could drive the delivery of an intracellular protein to the
extracellular space for its deposition beneath the glomerular
basement membrane. Nonetheless, we cannot rule out a role for
intracellular proteins and cryptic epitopes if we consider the
possibility of exposition of these antigens after podocyte injury by
C5b-9 attack complex. [17] Indeed, our results of immunofluo-
rescence basal patterns suggest a newfangled localization of SC65,
opening a parallel debate on the physiological function of this
protein in the cell.
Despite the strongly significant serologic results, histological
conclusions are not definitive for the lacking of clear subepithelial
localization of the antigen. We cannot exclude a technical limit of
our immunofluorescence histological analysis because the reagent
has not been certified for this purpose. Still, the number of patients
showing reactivity to the antigen is relevant and furthermore our
data suggest a clinical meaning for this association. Indeed positive
patients showed lower albumin and higher creatinine levels. We
can speculate that positive patients express a more clinically
relevant and aggressive disease, and this hypothesis is under
further investigation.
In conclusion, our report describes the finding of anti-SC65
antibodies in patients affected by iMN. The role of this antigen
under the diagnostic and prognostic value would be ascertained by
an extensive analysis of a large cohort of iMN patients that is
already in progress.
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